Dr. George D. Demetri on Trabectedin or Dacarbazine Treatments for Patients With Advanced Leiomyosarcoma or Liposarcoma
George D. Demetri, MD, director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, discusses the trial the led to the approval of trabectedin (Yondelis) for advanced leiomyosarcoma or liposarcoma.
George D. Demetri, MD, director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, discusses the trial the led to the approval of trabectedin (Yondelis) for advanced leiomyosarcoma or liposarcoma.
In this preplanned analysis, researchers were trying to limit any excess heterogeneity in order to get a clear answer as to whether trabectedin is more active than dacarbazine. There is no question, Demetri says, that there was a progression-free survival (PFS) difference but no overall survival (OS) difference.
Demetri says the lack of OS difference was due to post-study therapies virtually all patients went on to receive other agents after this protocol. It's worth noting, he says, that the trial was designed in 2010 and pazopanib (Votrient) was approved in 2012.
Lenalidomide Break Possible? Study Shows Hope for MRD-Negative Myeloma
October 7th 2024A new study suggests that patients with multiple myeloma who achieve sustained MRD-negativity for at least three years may be able to discontinue maintenance therapy without compromising their long-term outcomes.
Read More
